Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2026.1789896 Correction Correction: FGA modulates immune infiltration and tumor progression via SLC7A11/xCT-mediated disulfidptosis in the tumor microenvironment of lung adenocarcinoma LiGen 1 † Validation Project administration Visualization Writing – original draft Writing – review & editing Resources LiQiuping 2 3 † YangSheng 4 GuoDongmei 4 TaoYanling 3 JiaYan 3 * Department of Wound Reconstructive Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China Department of Clinical Medicine, Jining Medical University, Jining, China Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, China Weishan County People’s Hospital, Jining, China Correspondence: Yan Jia, 202036106@mail.sdu.edu.cn

These authors have contributed equally to this work

 17 02 2026 2026 17 1789896 17 01 2026 10 02 2026 17 01 2026 Copyright © 2026 Li, Li, Yang, Guo, Tao and Jia. 2026 Li, Li, Yang, Guo, Tao and Jia https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on FGA modulates immune infiltration and tumor progression via SLC7A11/xCT-mediated disulfidptosis in the tumor microenvironment of lung adenocarcinoma By Li G, Li Q, Yang S, Guo D, Tao Y and Jia Y (2025) Front. Immunol. 16:1595900. doi: 10.3389/fimmu.2025.1595900 immune infiltration disulfidptosis tumor microenvironment non-small-cell lung cancer lung adenocarcinoma section-at-acceptance Cancer Immunity and Immunotherapy

There was a mistake in Figure 7 as published. Figure 7 was inadvertently overwritten by an incorrect image. The corrected Figure 7 appears below.

Protein-protein interaction between FGA and xCT modulates progression and immune evasion in lung cancer. (A) Transwell migration and invasion assays were performed in a rescue experiment. (B) Wound healing assays were performed to detect cell migration in the rescue experiment. (C) Cell proliferation in the rescue experiment after 72h was detected by CCK8. (D) Endogenous FGA co-immunoprecipitates xCT in A549 cells. (E) Endogenous xCT co-immunoprecipitates FGA in A549 cells. (F) Immunostaining for xCT in A549 cell from the Human Protein Atlas. (G) Tumor cell FGA deficiency potentiates CD8+ T-cell activation via soluble factors in a non-contact Transwell co-culture system. (H) Immunohistochemical staining of FGA proteins in normal tissues and lung cancer from the Human Protein Atlas. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Panel A displays migration and invasion assays for A549 and NCI-H1299 cells with various treatments, alongside quantification bar graphs. Panel B shows wound healing assay images at zero, twenty-four, and forty-eight hours with corresponding migration area line graphs. Panel C presents cell proliferation bar graphs. Panels D and E display Western blot results for FGA and xCT protein interactions. Panel F contains immunofluorescence microscopy images of A549 cells highlighting xCT, nucleus, microtubules, and endoplasmic reticulum. Panel G includes bar graphs quantifying CD69 and CD25 expression. Panel H shows tissue microarray images with clinical information for lung and lung cancer samples stained for FGA.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Nahum Puebla-Osorio, University of Texas MD Anderson Cancer Center, United States